Namestnikova Daria D, Gubskiy Ilya L, Revkova Veronica A, Sukhinich Kirill K, Melnikov Pavel A, Gabashvili Anna N, Cherkashova Elvira A, Vishnevskiy Daniil A, Kurilo Victoria V, Burunova Veronica V, Semkina Alevtina S, Abakumov Maxim A, Gubsky Leonid V, Chekhonin Vladimir P, Ahlfors Jan-Eric, Baklaushev Vladimir P, Yarygin Konstantin N
Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russian Federation, Moscow, Russia.
Radiology and Clinical Physiology Scientific Research Center, Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russian Federation, Moscow, Russia.
Front Neurosci. 2021 Mar 2;15:641970. doi: 10.3389/fnins.2021.641970. eCollection 2021.
Cell therapy is an emerging approach to stroke treatment with a potential to limit brain damage and enhance its restoration after the acute phase of the disease. In this study we tested directly reprogrammed neural precursor cells (drNPC) derived from adult human bone marrow cells in the rat middle cerebral artery occlusion (MCAO) model of acute ischemic stroke using human placenta mesenchymal stem cells (pMSC) as a positive control with previously confirmed efficacy. Cells were infused into the ipsilateral (right) internal carotid artery of male Wistar rats 24 h after MCAO. The main goal of this work was to evaluate real-time distribution and subsequent homing of transplanted cells in the brain. This was achieved by performing intra-arterial infusion directly inside the MRI scanner and allowed transplanted cells tracing starting from their first pass through the brain vessels. Immediately after transplantation, cells were observed in the periphery of the infarct zone and in the brain stem, 15 min later small numbers of cells could be discovered deep in the infarct core and in the contralateral hemisphere, where drNPC were seen earlier and in greater numbers than pMSC. Transplanted cells in both groups could no longer be detected in the rat brain 48-72 h after infusion. Histological and histochemical analysis demonstrated that both the drNPC and pMSC were localized inside blood vessels in close contact with the vascular wall. No passage of labeled cells through the blood brain barrier was observed. Additionally, the therapeutic effects of drNPC and pMSC were compared. Both drNPC and pMSC induced substantial attenuation of neurological deficits evaluated at the 7th and 14th day after transplantation using the modified neurological severity score (mNSS). Some of the effects of drNPC and pMSC, such as the influence on the infarct volume and the survival rate of animals, differed. The results suggest a paracrine mechanism of the positive therapeutic effects of IA drNPC and pMSC infusion, potentially enhanced by the cell-cell interactions. Our data also indicate that the long-term homing of transplanted cells in the brain is not necessary for the brain's functional recovery.
细胞疗法是一种新兴的中风治疗方法,有望在疾病急性期限制脑损伤并促进其恢复。在本研究中,我们在大鼠急性缺血性中风大脑中动脉闭塞(MCAO)模型中测试了源自成人骨髓细胞的直接重编程神经前体细胞(drNPC),并使用人胎盘间充质干细胞(pMSC)作为具有先前确认疗效的阳性对照。在MCAO后24小时,将细胞注入雄性Wistar大鼠的同侧(右侧)颈内动脉。这项工作的主要目标是评估移植细胞在脑中的实时分布和随后的归巢情况。这是通过在MRI扫描仪内直接进行动脉内输注来实现的,并允许从移植细胞首次通过脑血管开始追踪它们。移植后立即在梗死区周边和脑干中观察到细胞,15分钟后在梗死核心深处和对侧半球发现少量细胞,其中drNPC比pMSC更早且数量更多。输注后48 - 72小时在大鼠脑中不再能检测到两组移植的细胞。组织学和组织化学分析表明,drNPC和pMSC都定位在血管内,与血管壁紧密接触。未观察到标记细胞穿过血脑屏障。此外,比较了drNPC和pMSC的治疗效果。使用改良神经功能缺损评分(mNSS)在移植后第7天和第14天评估,drNPC和pMSC均诱导神经功能缺损显著减轻。drNPC和pMSC的一些作用,如对梗死体积和动物存活率的影响有所不同。结果表明动脉内输注drNPC和pMSC产生积极治疗效果的旁分泌机制,可能通过细胞间相互作用得到增强。我们的数据还表明,移植细胞在脑中的长期归巢对于脑功能恢复并非必要。